Sodium glycerophosphate

Explore a selection of our essential drug information below, or:

CREATE FREE ACCOUNT

Full Drug Profiles

Unlock enhanced features & extensive drug insights, including detailed interaction data & regulatory status. Create a free account.

SUBSCRIBERECOMMENDED FOR PHARMA

Data Packages

Explore the full scope of our drug knowledge tailored for pharmaceutical research needs in our data library. Learn more.

Identification

Summary

Sodium glycerophosphate is a medication used to treat hypophosphatemia.

Brand Names

Glycophos, Olimel, Periolimel

Generic Name

Sodium glycerophosphate

DrugBank Accession Number

DB09561

Background

Sodium glycerophosphate is one of several glycerophosphate salts. It is used clinically to treat or prevent low phosphate levels ^Label. Glycerophosphate is hydrolyzed to inorganic phosphate and glycerol in the body ¹. The extent of this reaction is dependent on the activity of serum alkaline phosphatases.

Type

Small Molecule

Groups

Approved

Structure

Download

MOLSDFPDBSMILESInChI

Similar Structures

Structure for Sodium glycerophosphate (DB09561)

×

Close

Weight

Average: 216.036
Monoisotopic: 215.9775635

Chemical Formula

C₃H₇Na₂O₆P

Synonyms

• Disodium glycerol phosphate
• Sodium glycerophosphate anhydrous

Unlock the secrets to drugging the undruggable

Discover how groundbreaking research is turning "undruggable" targets into therapeutic opportunities.

Download eBook

Unlock the secrets to drugging the undruggable

Download eBook

Pharmacology

Indication

Sodium glycerophosphate is indicated for use as a source of phosphate in total parenteral nutrition ^Label. It is used in combination with amino acids, dextrose, lipid emulsions, and other electrolytes.

Reduce drug development failure rates

Build, train, & validate machine-learning models
with evidence-based and structured datasets.

See how

Build, train, & validate predictive machine-learning models with structured datasets.

See how

Associated Therapies

• Total parenteral nutrition therapy

Contraindications & Blackbox Warnings

Prevent Adverse Drug Events Today

Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.

Learn more

Avoid life-threatening adverse drug events with our Clinical API

Learn more

Pharmacodynamics

Glycerophosphate acts as a source of inorganic phosphate through hydrolysis ¹.

Mechanism of action

Sodium glycerophosphate acts as a donor of inorganic phosphate ¹. See Monopotassium phosphate for a description of phosphate's role in the body.

Absorption

Peak serum phosphate concentration is reached in 4h ¹.

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Glycerophosphate is hydrolyzed to form inorganic phosphate ¹. The extent of this reaction is dependent on serum alkaline phosphatase activity.

Route of elimination

Inorganic phosphate produced is eliminated in the urine ¹. There may be a very small amount of glycerophosphate excreted in the urine unchanged.

Half-life

Inorganic phosphate has a half-life of elimination of 2.06h ¹.

Clearance

Not Available

Adverse Effects

Improve decision support & research outcomes

With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!

See the data

Improve decision support & research outcomes with our structured adverse effects data.

See a data sample

Toxicity

Not Available

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

Not Available

Food Interactions

No interactions found.

Products

Drug product information from 10+ global regions

Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.

Access now

Access drug product information from over 10 global regions.

Access now

Product Ingredients

Ingredient	UNII	CAS	InChI Key
Sodium glycerophosphate hydrate	RCS9EQ01V4	55073-41-1	OFNNKPAERNWEDD-UHFFFAOYSA-L

Active Moieties

Name	Kind	UNII	CAS	InChI Key
Sodium cation	ionic	LYR4M0NH37	17341-25-2	FKNQFGJONOIPTF-UHFFFAOYSA-N

International/Other Brands

Glycophos (Fresenius Kabi Norge)

Brand Name Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End	Region	Image
Glycophos	Injection, solution	216 mg/1mL	Intravenous	Fresenius Kabi USA, LLC	2013-05-13	Not applicable

Over the Counter Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End	Region	Image
GLYCOPHOS CONCENTRATE FOR SOLUTION FOR INFUSION 216 mg/ml	Injection	216 mg/ml	Intravenous	FRESENIUS KABI (SINGAPORE) PTE LTD	2002-01-04	Not applicable

Mixture Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End	Region	Image
AMINOMIX	Sodium glycerophosphate hydrate (4.59 g/1000ml) + Acetic acid (4.5 g/1000ml) + Alanine (7 g/1000ml) + Arginine (6 g/1000ml) + Calcium chloride dihydrate (0.294 g/100ml) + Dextrose, unspecified form (120 g/100ml) + Glycine (5.5 g/1000ml) + Histidine (1.5 g/1000ml) + Hydrochloric acid (1.47 ml) + Isoleucine (2.5 g/1000ml) + Leucine (3.7 g/1000ml) + Lysine (3.3 g/1000ml) + Magnesium chloride hexahydrate (0.61 g/100ml) + Methionine (2.15 g/1000ml) + Phenylalanine (2.55 g/1000ml) + Potassium cation (30 mmol/l) + Potassium hydroxide (1.981 g/100ml) + Proline (5.6 g/1000ml) + Serine (3.25 g/1000ml) + Sodium cation (50 mmol/l) + Sodium chloride (1.169 g/100ml) + Taurine (0.5 g/1000ml) + Threonine (2.2 g/1000ml) + Tryptophan (1 g/1000ml) + Tyrosine (0.2 g/1000ml) + Valine (3.1 g/1000ml) + Zinc chloride (0.00545 g/100ml)	Injection, solution	Intravenous	Fresenius Kabi Italia S.R.L.	2014-07-08	Not applicable
AMINOMIX	Sodium glycerophosphate hydrate (4.59 g/1000ml) + Acetic acid (4.5 g/1000ml) + Alanine (7 g/1000ml) + Arginine (6 g/1000ml) + Calcium chloride dihydrate (0.294 g/100ml) + Dextrose, unspecified form (120 g/100ml) + Glycine (5.5 g/1000ml) + Histidine (1.5 g/1000ml) + Hydrochloric acid (1.47 ml) + Isoleucine (2.5 g/1000ml) + Leucine (3.7 g/1000ml) + Lysine (3.3 g/1000ml) + Magnesium chloride hexahydrate (0.61 g/100ml) + Methionine (2.15 g/1000ml) + Phenylalanine (2.55 g/1000ml) + Potassium cation (30 mmol/l) + Potassium hydroxide (1.981 g/100ml) + Proline (5.6 g/1000ml) + Serine (3.25 g/1000ml) + Sodium cation (50 mmol/l) + Sodium chloride (1.169 g/100ml) + Taurine (0.5 g/1000ml) + Threonine (2.2 g/1000ml) + Tryptophan (1 g/1000ml) + Tyrosine (0.2 g/1000ml) + Valine (3.1 g/1000ml) + Zinc chloride (0.00545 g/100ml)	Injection, solution	Intravenous	Fresenius Kabi Italia S.R.L.	2014-07-08	Not applicable
AMINOMIX	Sodium glycerophosphate hydrate (4.59 g/1000ml) + Acetic acid (4.5 g/1000ml) + Alanine (7 g/1000ml) + Arginine (6 g/1000ml) + Calcium chloride dihydrate (0.294 g/100ml) + Dextrose, unspecified form (200 g/100ml) + Glycine (5.5 g/1000ml) + Histidine (1.5 g/1000ml) + Hydrochloric acid (1.47 ml) + Isoleucine (2.5 g/1000ml) + Leucine (3.7 g/1000ml) + Lysine (3.3 g/1000ml) + Magnesium chloride hexahydrate (0.61 g/100ml) + Methionine (2.15 g/1000ml) + Phenylalanine (2.55 g/1000ml) + Potassium cation (30 mmol/l) + Potassium hydroxide (1.981 g/100ml) + Proline (5.6 g/1000ml) + Serine (3.25 g/1000ml) + Sodium cation (50 mmol/l) + Sodium chloride (1.169 g/100ml) + Taurine (0.5 g/1000ml) + Threonine (2.2 g/1000ml) + Tryptophan (1 g/1000ml) + Tyrosine (0.2 g/1000ml) + Valine (3.1 g/1000ml) + Zinc chloride (0.00545 g/100ml)	Injection, solution	Intravenous	Fresenius Kabi Italia S.R.L.	2014-07-08	Not applicable
AMINOMIX	Sodium glycerophosphate hydrate (4.59 g/1000ml) + Acetic acid (4.5 g/1000ml) + Alanine (7 g/1000ml) + Arginine (6 g/1000ml) + Calcium chloride dihydrate (0.294 g/100ml) + Dextrose, unspecified form (120 g/100ml) + Glycine (5.5 g/1000ml) + Histidine (1.5 g/1000ml) + Hydrochloric acid (1.47 ml) + Isoleucine (2.5 g/1000ml) + Leucine (3.7 g/1000ml) + Lysine (3.3 g/1000ml) + Magnesium chloride hexahydrate (0.61 g/100ml) + Methionine (2.15 g/1000ml) + Phenylalanine (2.55 g/1000ml) + Potassium cation (30 mmol/l) + Potassium hydroxide (1.981 g/100ml) + Proline (5.6 g/1000ml) + Serine (3.25 g/1000ml) + Sodium cation (50 mmol/l) + Sodium chloride (1.169 g/100ml) + Taurine (0.5 g/1000ml) + Threonine (2.2 g/1000ml) + Tryptophan (1 g/1000ml) + Tyrosine (0.2 g/1000ml) + Valine (3.1 g/1000ml) + Zinc chloride (0.00545 g/100ml)	Injection, solution	Intravenous	Fresenius Kabi Italia S.R.L.	2014-07-08	Not applicable
AMINOMIX	Sodium glycerophosphate hydrate (4.59 g/1000ml) + Acetic acid (4.5 g/1000ml) + Alanine (7 g/1000ml) + Arginine (6 g/1000ml) + Calcium chloride dihydrate (0.294 g/100ml) + Dextrose, unspecified form (120 g/100ml) + Glycine (5.5 g/1000ml) + Histidine (1.5 g/1000ml) + Hydrochloric acid (1.47 ml) + Isoleucine (2.5 g/1000ml) + Leucine (3.7 g/1000ml) + Lysine (3.3 g/1000ml) + Magnesium chloride hexahydrate (0.61 g/100ml) + Methionine (2.15 g/1000ml) + Phenylalanine (2.55 g/1000ml) + Potassium cation (30 mmol/l) + Potassium hydroxide (1.981 g/100ml) + Proline (5.6 g/1000ml) + Serine (3.25 g/1000ml) + Sodium cation (50 mmol/l) + Sodium chloride (1.169 g/100ml) + Taurine (0.5 g/1000ml) + Threonine (2.2 g/1000ml) + Tryptophan (1 g/1000ml) + Tyrosine (0.2 g/1000ml) + Valine (3.1 g/1000ml) + Zinc chloride (0.00545 g/100ml)	Injection, solution	Intravenous	Fresenius Kabi Italia S.R.L.	2014-07-08	Not applicable

Unapproved/Other Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End	Region	Image
Glycophos	Sodium glycerophosphate (216 mg/1mL)	Injection, solution	Intravenous	Fresenius Kabi USA, LLC	2013-05-13	Not applicable
GLYCOPHOSE IV INFUZYON ICIN STERIL APIROJEN SOLUSYON 10X20 ML FLAKON	Sodium glycerophosphate hydrate (216 mg)	Solution	Intravenous	FRESENİUS KABİ İLAÇ SAN. VE TİC. LTD. ŞTİ.	2020-08-14	2024-01-23
KABIVEN 1026 ML	Sodium glycerophosphate (1.5 g) + Alanine (4.8 g) + Arginine (3.4 g) + Aspartic acid (1 g) + Calcium chloride dihydrate (0.29 g) + D-glucose monohydrate (110 g) + Glutamic acid (1.7 g) + Glycine (2.4 g) + Histidine (2 g) + Isoleucine (1.7 g) + Leucine (2.4 g) + Lysine (2.7 g) + Magnesium sulfate heptahydrate (0.99 g) + Methionine (1.7 g) + Phenylalanine (2.4 g) + Potassium chloride (1.8 g) + Proline (2 g) + Serine (1.4 g) + Sodium acetate trihydrate (2.5 g) + Soybean oil (40 g) + Threonine (1.7 g) + Tryptophan (0.57 g) + Tyrosine (0.07 g) + Valine (2.2 g)	Injection	Intravenous	FRESENİUS KABİ İLAÇ SAN. VE TİC. LTD. ŞTİ.	2013-01-29	2022-11-10
KABIVEN 1540 ML	Sodium glycerophosphate (2.3 g) + Alanine (7.2 g) + Arginine (5.1 g) + Aspartic acid (1.5 g) + Calcium chloride dihydrate (0.44 g) + D-glucose monohydrate (165 g) + Glutamic acid (2.5 g) + Glycine (3.6 g) + Histidine (3.1 g) + Isoleucine (2.5 g) + Leucine (3.6 g) + Lysine (4.1 g) + Magnesium sulfate heptahydrate (1.5 g) + Methionine (2.5 g) + Phenylalanine (3.6 g) + Potassium chloride (2.7 g) + Proline (3.1 g) + Serine (2 g) + Sodium acetate trihydrate (3.7 g) + Soybean oil (60 g) + Threonine (2.5 g) + Tryptophan (0.86 g) + Tyrosine (0.1 g) + Valine (3.3 g)	Injection	Intravenous	FRESENİUS KABİ İLAÇ SAN. VE TİC. LTD. ŞTİ.	2013-01-29	2022-11-10
KABIVEN 2053 ML	Sodium glycerophosphate (3 g) + Alanine (9.6 g) + Arginine (6.8 g) + Aspartic acid (2 g) + Calcium chloride dihydrate (0.59 g) + D-glucose monohydrate (220 g) + Glutamic acid (3.4 g) + Glycine (4.7 g) + Histidine (4.1 g) + Isoleucine (3.4 g) + Leucine (4.7 g) + Lysine (5.4 g) + Magnesium sulfate heptahydrate (2 g) + Methionine (3.4 g) + Phenylalanine (4.7 g) + Potassium chloride (3.6 g) + Proline (4.1 g) + Serine (2.7 g) + Sodium acetate trihydrate (4.9 g) + Soybean oil (80 g) + Threonine (3.4 g) + Tryptophan (1.1 g) + Tyrosine (0.14 g) + Valine (4.4 g)	Injection	Intravenous	FRESENİUS KABİ İLAÇ SAN. VE TİC. LTD. ŞTİ.	2013-01-29	2022-11-10

Categories

ATC Codes

B05XA14 — Sodium glycerophosphate

• B05XA — Electrolyte solutions
• B05X — I.V. SOLUTION ADDITIVES
• B05 — BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
• B — BLOOD AND BLOOD FORMING ORGANS

Drug Categories

• Alcohols
• Blood and Blood Forming Organs
• Blood Substitutes and Perfusion Solutions
• Carbohydrates
• Electrolyte Solutions
• I.V. Solution Additives
• Lipids
• Membrane Lipids
• Phosphate salts
• Phospholipids
• Sugar Alcohols
• Sugar Phosphates
• Triose Sugar Alcohols

Chemical TaxonomyProvided by Classyfire

Description

This compound belongs to the class of organic compounds known as glycerophosphates. These are compounds containing a glycerol linked to a phosphate group.

Kingdom

Organic compounds

Super Class

Lipids and lipid-like molecules

Class

Glycerophospholipids

Sub Class

Glycerophosphates

Direct Parent

Glycerophosphates

Alternative Parents

Alkyl phosphates / Secondary alcohols / 1,2-diols / Primary alcohols / Organic sodium salts / Organic oxides / Hydrocarbon derivatives

Substituents

1,2-diol / Alcohol / Aliphatic acyclic compound / Alkyl phosphate / Hydrocarbon derivative / Organic alkali metal salt / Organic oxide / Organic oxygen compound / Organic phosphoric acid derivative / Organic salt

Molecular Framework

Aliphatic acyclic compounds

External Descriptors

Not Available

Affected organisms

Not Available

Chemical Identifiers

UNII

G43E72677U

CAS number

1334-74-3

InChI Key

GEKBIENFFVFKRG-UHFFFAOYSA-L

InChI

InChI=1S/C3H9O6P.2Na/c4-1-3(5)2-9-10(6,7)8;;/h3-5H,1-2H2,(H2,6,7,8);;/q;2*+1/p-2

IUPAC Name

disodium 3-(phosphonooxy)propane-1,2-diol

SMILES

[Na+].[Na+].OCC(O)COP([O-])([O-])=O

References

General References

1. Topp H, Hochfeld O, Bark S, Grossmann M, Joukhadar C, Westphal M, Straatsma H, Rothenburger M: Glycerophosphate is interchangeable with inorganic phosphate in terms of safety and serum pharmacokinetics. Pharmacology. 2011;88(3-4):193-200. doi: 10.1159/000331341. Epub 2011 Oct 4. [Article]

External Links

PubChem Compound

22251426

PubChem Substance

347827880

ChemSpider

14071

RxNav

1595589

ChEMBL

CHEMBL3040581

FDA label

Download (806 KB)

MSDS

Download (46.7 KB)

Clinical Trials

Clinical Trials

Clinical Trial & Rare Diseases Add-on Data Package

Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package

Phase	Status	Purpose	Conditions	Count	Start Date	Why Stopped	100+ additional columns
Unlock 175K+ rows when you subscribe.View sample data
Not Available	Completed	Supportive Care	Mechanical Ventilation	1	somestatus	stop reason	just information to hide
Not Available	Completed	Treatment	Hematological Malignancy	1	somestatus	stop reason	just information to hide
4	Recruiting	Prevention	Intestinal Obstruction / Laparotomies / Mesenteric vascular insufficiency	1	somestatus	stop reason	just information to hide
4	Terminated	Supportive Care	Cancer-related Malnutrition	1	somestatus	stop reason	just information to hide
4	Terminated	Supportive Care	Critically Ill Patients	1	somestatus	stop reason	just information to hide

Unlock 75,000+ rows when you subscribe

Explore data packages curated & structured to speed up your pharmaceutical research

View Sample Data

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage Forms

Form	Route	Strength
Injection, solution	Intravenous
Injection, solution	Intramuscular
Syrup	Oral
Tablet	Oral
Injection	Intravenous
Injection, solution	Intravenous	216 mg/1mL
Solution	Intravenous	216 mg/1ml
Injection, solution, concentrate	Intravenous	6 g/20ml
Injection	Intravenous	216 mg/ml
Injection, solution	Intravenous	216 mg/mL
Solution	Intravenous	216 mg
Emulsion	Parenteral	20.000 g
Injection, emulsion	Intravenous
Injection	Intravenous
Injection	Intravenous	1.6 g/l
Injection, emulsion	Parenteral
Emulsion	Intravenous
Emulsion	Intravenous	0.466 g
Injection, emulsion; injection, solution	Intravenous
Solution	Intravenous
Emulsion	Intravenous	4 g
Emulsion	Intravenous	3 g
Emulsion	Intravenous	13.000 g
Emulsion	Parenteral
Liquid	Oral

Prices

Not Available

Patents

Not Available

Properties

State

Solid

Experimental Properties

Property	Value	Source
water solubility	Soluble	MSDS

Predicted Properties

Property	Value	Source
Water Solubility	81.5 mg/mL	ALOGPS
logP	-1.4	ALOGPS
logP	-2	Chemaxon
logS	-0.42	ALOGPS
pKa (Strongest Acidic)	1.51	Chemaxon
pKa (Strongest Basic)	-3	Chemaxon
Physiological Charge	-2	Chemaxon
Hydrogen Acceptor Count	5	Chemaxon
Hydrogen Donor Count	2	Chemaxon
Polar Surface Area	112.88 Å2	Chemaxon
Rotatable Bond Count	4	Chemaxon
Refractivity	29.15 m3·mol-1	Chemaxon
Polarizability	12.87 Å3	Chemaxon
Number of Rings	0	Chemaxon
Bioavailability	1	Chemaxon
Rule of Five	Yes	Chemaxon
Ghose Filter	No	Chemaxon
Veber's Rule	No	Chemaxon
MDDR-like Rule	No	Chemaxon

Predicted ADMET Features

Not Available

Spectra

Mass Spec (NIST)

Not Available

Spectra

Not Available

Chromatographic Properties

Collision Cross Sections (CCS)

Adduct	CCS Value (Å2)	Source type	Source
[M-H]-	120.83506	predicted	DeepCCS 1.0 (2019)
[M+H]+	123.74898	predicted	DeepCCS 1.0 (2019)
[M+Na]+	132.5454	predicted	DeepCCS 1.0 (2019)

×

Identify potential medication risks

Easily compare up to 40 drugs with our drug interaction checker.

Get severity rating, description, and management advice.

Learn more

Drug created at November 30, 2015 19:10 / Updated at February 13, 2021 11:02